poloxalene has been researched along with Hepatocellular Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, S; Chen, L; Gan, H; Li, A; Liang, Y; Liu, X; Sui, X; Tang, X; Wang, D; Wu, B; Zhang, Y; Zou, S | 1 |
| Arima, K; Kodama, T; Sakamoto, H; Suga, M; Yachi, A | 1 |
2 other study(ies) available for poloxalene and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; Drug Delivery Systems; HeLa Cells; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Nude; Nanoparticles; Poloxalene; Polyesters; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
[Pharmacological and clinical studies on lipiodol emulsion for hepatocellular carcinoma].
Topics: Animals; Carcinoma, Hepatocellular; Doxorubicin; Embolization, Therapeutic; Emulsions; Hepatic Artery; Humans; Iodized Oil; Liver Neoplasms; Liver Neoplasms, Experimental; Poloxalene; Rats | 1988 |